Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458506071172v1
13/3/343    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Rezze, S.
Right arrow Articles by Bagnato, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Rezze, S.
Right arrow Articles by Bagnato, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on April 1, 2007
Multiple Sclerosis, Vol. 13, No. 3, 343-347 (2007)
DOI: 10.1177/1352458506071172

An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis

S. Di Rezze

Department of Neurological Sciences, La Sapienza University, Rome, Italy

S. Gupta

New York Medical College, Valhalla, NY 10595, USA, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA

V. Durastanti

Department of Neurological Sciences, La Sapienza University, Rome, Italy

E. Millefiorini

Department of Neurological Sciences, La Sapienza University, Rome, Italy

C. Pozzilli

Department of Neurological Sciences, La Sapienza University, Rome, Italy

F. Bagnato

Department of Neurological Sciences, La Sapienza University, Rome, Italy, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA, bagnatof{at}ninds.nih.gov

Sixty-two patients with multiple sclerosis (MS) were imaged monthly over a six-month (ie, seven monthly magnetic resonance images [MRI]) natural history period (NHP). Thereafter, patients were randomized to receive 11 or 33 µg of subcutaneously injected interferon beta 1a (IFNp-1 a) with imaging monthly for nine months and at months 12, 18 and 24 of therapy phase (TP). In the present exploratory post hoc analysis, the authors evaluated IFNß-1a dose effect on reducing the size of contrast-enhancing lesions (CELs). MRIs performed at months 0, 3 and 6 of NHP and at months 3, 6, 9, 18 and 24 of TP were analysed. While a significant reduction in mean number of CELs was observed in both treatment groups of patients, the mean total volume and size of CELs was reduced only in patients undergoing therapy with 33 µg of IFNß-1a. The latter suggests a significant dose effect exerted by IFNß-1a in the evolution of CELs' dimensions during therapy. Multiple Sclerosis 2007; 13: 343-347. http://msj.sagepub.com

Key Words: contrast-enhancing lesions • inflammation • interferon beta • lesion size • magnetic resonance imaging • multiple sclerosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?